Tess V. Dupre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tess V. Dupre has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Parag P. Shah
Departments of Pharmacology and Medicine, University of Louisville, Louisville, KY
3 shared publicationsCierra N. Sharp
Departments of Pharmacology and Toxicology University of Louisville, Louisville, KY
2 shared publicationsDeanna Siow
Departments of Pharmacology and Toxicology University of Louisville, Louisville, KY
2 shared publicationsJudit Megyesi
Department of Internal Medicine, Division of Nephrology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
2 shared publications- Leah J. Siskind
University of Louisville
2 shared publications Levi J. Beverly
Departments of Pharmacology and Toxicology University of Louisville, Louisville, KY
2 shared publications
Latest Publications
- 1 January 2018
- Published by Elsevier
- p. 452-486
Renal Toxicology/Nephrotoxicity of Cisplatin and Other Chemotherapeutic Agents
- 1 January 2018
- Published by Elsevier
- p. 452-486
Renal Toxicology/Nephrotoxicity of Cisplatin and Other Chemotherapeutic Agents
- Open Access
- 1 July 2017
- Published by Elsevier in Journal of Lipid Research
- Vol. 58 (7) , 1439-1452
Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury
- 1 July 2017
- Published by Elsevier in Journal of Lipid Research
- Vol. 58 (7) , 1439-1452
Open AccessInhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury
- Open Access
- 7 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (14) , 22625-22639
Common cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress
Common cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress
- 7 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (14) , 22625-22639
Open AccessCommon cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress
Common cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress
- 15 March 2016
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 310 (6) , F560-F568
Repeated administration of low-dose cisplatin in mice induces fibrosis
Cisplatin, a chemotherapeutic used for the treatment of solid cancers, has nephrotoxic side effects leading to acute kidney injury (AKI). Cisplatin cannot be given to patients that have comorbidities that predispose them to an increased risk for AKI. Even without these comorbidities, 30% of patients administered cisplatin will develop kidney injury, requiring the oncologist to withhold or reduce the next dose, leading to a less effective therapeutic regimen. Although recovery can occur after one episode of cisplatin-induced AKI, longitudinal studies have indicated that multiple episodes of AKI lead to the development of chronic kidney disease, an irreversible disease with no current treatment. The standard mouse model of cisplatin-induced AKI consists of one high dose of cisplatin (>20 mg/kg) that is lethal to the animal 3 days later. This model does not accurately reflect the dosing regimen patients receive nor does it allow for the long-term study of kidney function and biology. We have developed a repeated dosing model whereby cisplatin is given once a week for 4 wk. Comparison of the repeated dosing model with the standard dosing model demonstrated that inflammatory cytokines and chemokines were induced in the repeated dosing model, but levels of cell death were lower in the repeated dosing model. The repeated dosing model had increased levels of fibrotic markers (fibronectin, transforming growth factor-β, and α-smooth muscle actin) and interstitial fibrosis. These data indicate that the repeated dosing model can be used to study the AKI to chronic kidney disease progression as well as the mechanisms of this progression.
- 15 March 2016
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 310 (6) , F560-F568
Repeated administration of low-dose cisplatin in mice induces fibrosis
Cisplatin, a chemotherapeutic used for the treatment of solid cancers, has nephrotoxic side effects leading to acute kidney injury (AKI). Cisplatin cannot be given to patients that have comorbidities that predispose them to an increased risk for AKI. Even without these comorbidities, 30% of patients administered cisplatin will develop kidney injury, requiring the oncologist to withhold or reduce the next dose, leading to a less effective therapeutic regimen. Although recovery can occur after one episode of cisplatin-induced AKI, longitudinal studies have indicated that multiple episodes of AKI lead to the development of chronic kidney disease, an irreversible disease with no current treatment. The standard mouse model of cisplatin-induced AKI consists of one high dose of cisplatin (>20 mg/kg) that is lethal to the animal 3 days later. This model does not accurately reflect the dosing regimen patients receive nor does it allow for the long-term study of kidney function and biology. We have developed a repeated dosing model whereby cisplatin is given once a week for 4 wk. Comparison of the repeated dosing model with the standard dosing model demonstrated that inflammatory cytokines and chemokines were induced in the repeated dosing model, but levels of cell death were lower in the repeated dosing model. The repeated dosing model had increased levels of fibrotic markers (fibronectin, transforming growth factor-β, and α-smooth muscle actin) and interstitial fibrosis. These data indicate that the repeated dosing model can be used to study the AKI to chronic kidney disease progression as well as the mechanisms of this progression.
- 22 February 2016
- Published by University of Louisville
Suramin protects from cisplatin-induced acute kidney injury.
In rodent models, suramin improves recovery following acute kidney injury (AKI). We hypothesized that suramin would be useful in protection against cisplatin-induced AKI. This hypothesis was tested by pre-treating C57BL/6j mice with suramin prior to cisplatin. Our data indicates that suramin protects the kidney from injury by decreasing cisplatininduced decreases in kidney function. Renal histology indicated that suramin significantly protected from cisplatin-induced AKI. Data indicate that suramin pretreatment attenuated mRNA expression of pro-inflammatory cytokines and chemokines following cisplatin treatment, while also decreasing markers of cell stress and cell death. We utilized the same experimental design with 10-month old FVB mice expressing mutant Kras driven lung adenocarcinomas. Assessment of lung histology and kidney function indicated that suramin protected mice from cisplatin-induced AKI and did not inhibit cisplatin’s anti-tumor efficacy. These results suggest that suramin shows great potential as a renoprotective agent for the treatment/ prevention of cisplatininduced AKI.
- 22 February 2016
- Published by University of Louisville
Suramin protects from cisplatin-induced acute kidney injury.
In rodent models, suramin improves recovery following acute kidney injury (AKI). We hypothesized that suramin would be useful in protection against cisplatin-induced AKI. This hypothesis was tested by pre-treating C57BL/6j mice with suramin prior to cisplatin. Our data indicates that suramin protects the kidney from injury by decreasing cisplatininduced decreases in kidney function. Renal histology indicated that suramin significantly protected from cisplatin-induced AKI. Data indicate that suramin pretreatment attenuated mRNA expression of pro-inflammatory cytokines and chemokines following cisplatin treatment, while also decreasing markers of cell stress and cell death. We utilized the same experimental design with 10-month old FVB mice expressing mutant Kras driven lung adenocarcinomas. Assessment of lung histology and kidney function indicated that suramin protected mice from cisplatin-induced AKI and did not inhibit cisplatin’s anti-tumor efficacy. These results suggest that suramin shows great potential as a renoprotective agent for the treatment/ prevention of cisplatininduced AKI.
- 19 February 2014
- Published by Elsevier in Journal of Surgical Research
- Vol. 190 (1) , 111-118
Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor
- 19 February 2014
- Published by Elsevier in Journal of Surgical Research
- Vol. 190 (1) , 111-118
Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor